Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Mono or Dual-Ligand Nanoparticles: Theoretical Study

Ebtisam A Aldaais*

Dual-ligand nanocarriers have been developed to target over-expressed receptors, such as epidermal growth factor receptors (EGFR) and folate receptors (FR), in cancer cells. The dual ligand technique has been developed to enhance nanocarrier targeting, by binding to two kinds of over-expressed receptors instead of one. This study theoretically designs the binding of dual-ligand to two types of over-expressed receptors on cancer cells. We developed molecular theory that considers van der Waals, steric, and electrostatic interactions under a decoupled self-consistent field (SCF) approach. Our developed theory determines the dual-ligand-receptor binding regulations, and it can be applied for triple-ligand nanocarriers. The developed theory shows that dual-ligand nanocarriers are more effective than two mono-ligand nanocarriers combined. Manipulating some of the environmental parameters, such as salt concentration, temperature, and pH, along with the design parameters, such as polyelectrolytes pKa, number of polymers, and their density, can improve the functionality of the therapeutic nanocarriers. Besides, the size of the targeted nanocarriers is determined in this work to an efficient binding to two or more receptors on the cancer cell.